REVCON Virtual is happening soon! Two days dedicated to mastering the revenue  cycle | Register Today!

NHIC Updates Stand on Avastin Use

  • By
  • In Billing
  • February 11, 2011
  • Comments Off on NHIC Updates Stand on Avastin Use

Effective for services rendered on or after Feb. 1, NHIC, Corp. will allow no greater than two units of HCPCS Level II code J9035 Injection, bevacizumab, 10 mg per patient per date of service. This accommodates right and left eyes being treated on the same date of service.
Literature indicates, however, that the anticipated dosage is 1.25 mg or less for ophthalmological conditions; and the smallest currently available vial of bevacizumab (Avastin®) contains 100 mg.
In an education article posted Feb. 3 on the contractor’s website, the Medicare Part B contractor for jurisdiction 14 urges providers to have the drug prepared by a compounding pharmacist to avoid the significant amount of wastage that would occur if used for a single patient.
NHIC also reminds physicians that medical necessity for J9035 is supported by disorders of the eye and adnexa ICD-9-CM diagnosis codes: 362.01-362.07, 362.15, 362.16, 362.29, 362.30, 362.35, 362.36, 362.52, 362.53, 362.83, 362.84, 364.42, 365.63, and 365.89.
Source: NHIC, Corp.

No Responses to “NHIC Updates Stand on Avastin Use”

  1. Karen Connors says:

    I have been looking for medical necessary diagnosis for the use of this medication in oncology/hematology since this is a medicine which is widely used in this area. Nothing that I have found via CMS has addressed the non-ophthalmological use.